The traditional drug discovery process is slow and costly, typically taking 12 to 15 years from regulatory development to final approval. This approach is particularly ineffective in public health emergencies or when dealing with rare diseases that affect only a small portion of the population\u2014situations where industry and private investment opportunities are limited compared to the high costs of development processes.<\/p>\n
In this context, drug repurposing has emerged as an alternative strategy to accelerate treatment development. It involves finding new therapeutic uses for already known drugs, leveraging existing information about their safety, efficacy, and manufacturing processes.<\/p>\n
This approach allows drug repurposing to bypass the initial stages of clinical development and phase I clinical trials. With this strategy, after in vitro and in vivo studies, the process moves directly to phase II clinical trials, where treatment in patients will confirm or disprove its therapeutic efficacy.<\/p>\n <\/p>\n This advancement significantly reduces the time and cost compared to the traditional drug development process. Moreover, by building on existing knowledge of drug safety and clinical use, it minimizes risks and reduces uncertainty in the development process, enabling a faster response in health emergencies.<\/p>\n![\"Image](\"https:\/\/interreg-sudoe.eu\/wp-content\/uploads\/2025\/05\/Graficas-RePo-300x225.png\")
![\"Image](\"https:\/\/interreg-sudoe.eu\/wp-content\/uploads\/2025\/05\/Graficas-RePo-1-300x225.png\")